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Regulatory B cells control inflammation and autoimmunity in mice, including the recently 
identified IL-10-competent B10 cell subset that represents 1-3% of spleen B cells. In this study, a 
comparable IL-10-competent B10 cell subset was characterized in human blood. B10 cells were 
functionally identified by their ability to express cytoplasmic IL-10 following 5 h of ex vivo 
stimulation, while progenitor B10 (B10pro) cells required 48 h of in vitro stimulation before they 
acquired the ability to express IL-10. B10 and B10pro cells represented 0.6% and ~5% of blood 
B cells, respectively. Ex vivo B10 and B10pro cells were predominantly found within the 
CD24hiCD27+ B cell subpopulation that was able to negatively regulate monocyte cytokine 
production through IL-10-dependent pathways during in vitro functional assays. Blood B10 cells 
were present in ninety-one patients with rheumatoid arthritis, systemic lupus erythematosus, 
primary Sjögren’s syndrome, autoimmune vesiculobullous skin disease, or multiple sclerosis, and 
were expanded in some cases as occurs in mice with autoimmune disease. Mean B10+B10pro 
cell frequencies were also significantly higher in patients with autoimmune disease when 
compared with healthy controls. The characterization of human B10 cells will facilitate their 
identification and the study of their regulatory activities during human disease. 
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Introduction 
B cells are generally considered to positively regulate immune responses by producing 
antigen-specific Ab and helping to induce optimal CD4+ T cell activation.1 However, B cells and 
specific B cell subsets can also negatively regulate immune responses in mice.2-6 The absence or 
loss of these regulatory B cells exacerbates disease symptoms in contact hypersensitivity, 
experimental autoimmune encephalomyelitis, chronic colitis, collagen-induced arthritis, and in 
lupus-like models of autoimmunity.7-15 In many of these cases, B cells regulate inflammation, 
asthma, and T cell-mediated autoimmunity through the production of IL-10.8-10,12-16 Both human 
and mouse IL-10 exhibit numerous pleiotropic activities in vitro and in vivo, including 
suppression of both Th1 and Th2 polarization and inhibition of antigen presentation and 
proinflammatory cytokine production by dendritic cells, monocytes and macrophages.17 
In mice, a subset of IL-10-competent regulatory B cells can be functionally identified by their 
ability to express cytoplasmic IL-10 following 5 h of in vitro stimulation with LPS, PMA, and 
ionomycin, with monensin included in the cultures to block IL-10 secretion.12,13 These IL-10-
competent B cells have been labeled as B10 cells to identify them as the predominant, if not 
exclusive, source of B cell IL-10 production and to distinguish them from other regulatory B cell 
subsets that may also exist.5 For example, inducible IL-12-producing B cells regulate intestinal 
inflammation.18 B10 cells are found within the spleens of naïve wild type mice at frequencies of 
1-3%, where they predominantly represent a subset of the phenotypically unique 
CD1dhiCD5+CD19hi B cell subpopulation that shares overlapping cell surface markers with 
multiple phenotypically-defined B cell subsets.11-14,19,20 Additional B cells within the 
CD1dhiCD5+ B cell subpopulation acquire the ability to function like B10 cells during 48 h of in 
vitro stimulation with LPS or agonistic CD40 mAb.5 These B10 progenitor (B10pro) cells are 
then able to express cytoplasmic IL-10 following stimulation with PMA, ionomycin and 
monensin for 5 h.21 B10 cells also require diverse B cell antigen receptors for their 
development21 and their regulatory functions are Ag-restricted in vivo.12,13 Spleen B10 cell 
numbers increase significantly in diabetes- and lupus-prone mice14,21, and the adoptive transfer of 
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antigen-primed CD1dhiCD5+ B cells reduces inflammation during contact hypersensitivity and 
autoimmune disease.12,13,22 
The identification and characterization of an IL-10-producing B cell subset in mice raises the 
issue of whether B cells with these functional properties exist in man. Studies of B cell IL-10 
production in humans have yielded diverse results that are currently difficult to unify into a 
coherent model.23-28 It is also unknown whether human B10 cells share overlapping physiologic 
triggers with mouse B10 cells that lead to IL-10 production and their expansion in vitro.12,13,21 
Therefore, the purpose of the current study was to enumerate and characterize the IL-10 
competent B10 and B10pro cell subsets in humans. 
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Materials and Methods 
Cells 
Heparinized blood was obtained from healthy donors, ages 14-73, or from patients. Patients with 
rheumatoid arthritis met the American College of Rheumatology 1987 revised classification 
criteria.30 Patients with systemic lupus erythematosus satisfied the 1982 classification criteria.31 
Patients with primary Sjögren’s syndrome fulfilled the American-European consensus group 
criteria.32 Patients with autoimmune vesiculobullous skin disease, including bullous pemphigoid, 
pemphigus foliaceus, pemphigus vulgaris, and dermatitis herpetiformis had typical clinical and 
histologic findings, with diagnostic findings on direct immunofluroesence of perilesional skin or 
oral mucosa.33,34 Patients with multiple sclerosis fulfilled the 2005 McDonald criteria for 
relapsing remitting or primary progressive multiple sclerosis,35 or secondary progressive multiple 
sclerosis as defined using the Lublin and Reingold criteria.36 Tissues were obtained anonymously 
from individuals without identifiable hematologic disorders, with the purified B cells 
immediately cryopreserved (>90% cell viability). Cryopreserved cord blood samples were 
obtained from the Duke University Stem Cell Laboratory and the Carolinas Cord Blood Bank. 
Blood mononuclear cells were isolated by centrifugation over a discontinuous Lymphoprep 
(Axis-Shield PoC As, Oslo, Norway) gradient. Cell numbers were quantified by hemocytometer, 
with relative lymphocyte percentages among viable cells (based on scatter properties) determined 
by flow cytometry. In some experiments, B cells were enriched using RosetteSep (STEMCELL 
Technologies, Vancouver, BC, Canada) following the manufacturer’s protocols. CD19-mAb 
coated microbeads (Miltenyi Biotech) were used to purify blood B cells by positive selection 
following the manufacturer’s instructions. When necessary, the cells were enriched a second time 
using a fresh MACS column to obtain >99% purities. 
Written informed consent was obtained in all cases according to the Declaration of Helsinki. 
All protocols were approved by the respective ethics boards; Institutional Review Board of Duke 
University Medical Center, the Human Protection Committee of Dana-Farber Cancer 
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Institute/Harvard Medical School, University of Rochester Institutional Review Board, and the 
Institutional Review Board of St. Luke’s–Roosevelt Hospital Center Institute for Health Sciences. 
 
Antibodies, immunofluorescence analysis and cell sorting 
Anti-human mAbs included: IgD (IA6-2) from BD PharMingen (San Diego, CA); CD21 (BU33), 
CD22 (RFB4), CD23 (D.6) from Ancell (Bayport, MN); IgM (MHM-88), CD1d (51.1), CD5 
(UCHT2), CD19 (HIB19), CD24 (ML5), CD25 (BC96), CD27 (O323), CD38 (HIT2), CD40 
(HB14), CD48 (BJ40), and CD148 (A3), TNFα (MAb11), functional grade CD3 (HIT3a), and 
phycoerythrin-conjugated or unconjugated anti-IL-10 mAb (JES3-19F1) mAbs from BioLegend 
(San Diego, CA). Anti-human IgM Ab was from Jackson ImmunoResearch Laboratories, Inc. 
(West Grove, PA).  
Single cell suspensions were stained on ice using predetermined optimal concentrations of 
each Ab for 20-60 min, and fixed as described.29 Cells with the light scatter properties of 
lymphocytes were analyzed by 2-6 color immunofluorescence staining and FACScan or 
FACSCalibur flow cytometers (Becton Dickinson, San Jose, CA). Dead cells were excluded 
from the analysis based on their forward- and side-light scatter properties and the use of 
LIVE/DEAD® Fixable Violet Dead Cell Stain Kits (Invitrogen-Molecular Probes, Carlsbad, CA). 
All histograms are shown on a 4-decade logarithmic scale, with gates shown to indicate 
background isotype-matched control mAb staining set with <2% of the cells being positive. 
Blood CD24hiCD27+ and CD24lowCD27- B cells were isolated using a FACSVantage SE flow 
cytometer (Becton Dickinson) with 90-95% purities. 
 
Analysis of IL-10 production 
Intracellular IL-10 analysis by flow cytometry was as described.12 Briefly, cells were resuspended 
(2 x 106 cells/ml) in medium [RPMI 1640 media containing 10% FCS, 200 µg/ml penicillin, 200 
U/ml streptomycin, and 4 mM L-Glutamine (all from Gibco, Carlsbad, CA)] and stimulated with 
LPS (10 µg/ml, Escherichia coli serotype 0111: B4; Sigma), CpG (ODN 2006, 10 µg/ml; 
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Invivogen), or other TLR agonists (TLR1, Pam3CSK4, 1 µg/ml; TLR2, heat-killed Listeria 
monocytogenes, 108 cells/ml; TLR3, Poly(I:C), 10 µg/ml; TLR5, S. typhimurium flagellin, 1 
µg/ml; TLR6, Pam2CGDPKHPKSF, 1 µg/ml; TLR7, Imiquimod, 1 µg/ml; TLR8, ssRNA40, 1 
µg/ml; Invivogen), CD40L (1 µg/ml; R&D Systems, Minneapolis, MN), anti-human CD40 mAb 
(1 µg/ml; BioLegend), PMA (50 ng/ml; Sigma), ionomycin (1 µg/ml; Sigma), Brefeldin A (1X 
solution/ml; BioLegend), monensin (2 mM; eBioscience), and anti-IgM antibody (10 µg/ml) as 
indicated in 48-well flat-bottom plates before staining and flow cytometry analysis. For analysis 
of cell proliferation, lymphocytes were stained with CFSE Vybrant™  CFDA SE fluorescent dye 
(5 µM; Invitrogen-Molecular Probes) according to the manufacturer’s instructions. For IL-10 
detection, Fc receptors were blocked using FcγR-Binding inhibitor (eBioscience). Stained cells 
were fixed and permeabilized using a Cytofix/Cytoperm kit (BD PharMingen) according to the 
manufacturer’s instructions and stained with anti-IL-10 mAb.  
Secreted IL-10 was quantified by ELISA. Purified B cells (4 x 105) were cultured in 0.2 ml of 
complete medium in a 96-well flat-bottom tissue culture plates. Culture supernatant fluid IL-10 
concentrations for triplicate samples were quantified using IL-10 OptEIA ELISA kits (BD 
PharMingen) following the manufacturer’s protocols. 
 
Il10 transcript expression 
In some experiments, IL-10-secreting blood B cells were identified after 4 h of in vitro 
stimulation using an IL-10 secretion detection kit (Miltenyi Biotech, Auburn, CA) with 
subsequent staining for CD19 expression before cell sorting into IL-10+CD19+ and IL-10-CD19+ 
populations. RNA extraction, cDNA generation, and real-time PCR analysis was as described.13 
IL-10 primers were: sense 5’-CTTCGAGATC TCCGAGATGC CTTC-3’, antisense 5’-
ATTCTTCACC TGCTCCACGG CCTT-3’. GAPDH primers were: sense 5’-GCCACCCAGA 
AGACTGTGGA TGGC-3’ and antisense 5’-CATGTAGGCC ATGAGGTCCA CCAC-3’. 
 
In vitro functional assays 
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Blood CD24hiCD27+CD19+ and CD24lowCD27-CD19+ B cells from healthy controls were 
purified by cell sorting and stimulated with CpG (10 µg/ml) plus CD40L (1 µg/ml) for 24 h. 
Naïve CD4+CD25- T cells were purified by MACS (Miltenyi Biotech), and cultured in replicate 
wells either alone (1x106/ml) or with CD40/CpG-stimulated B cells (1x106/ml) in tissue culture 
plates coated with CD3 mAb (0.5 µg/ml) for 72 h with either BFA or PIB added during the final 
5 hours. The cells were stained for cell surface CD4 and cytoplasmic TNF-α expression before 
analysis by flow cytometry. Alternatively, CD40/CpG-stimulated sorted B cell populations 
(1x106/ml) were cultured for 20 h with equal numbers of blood monocytes that had been purified 
by plastic adherence or MACS, with anti-IL-10 mAb (10 µg/ml) added to some cultures. The 
cultured cells were then washed, stimulated with LPS (1 µg/ml) for 4 h in the presence of BFA, 




All data are shown as means (±SEM). Significant differences between sample means were 
determined using the Student’s t test. 
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Results 
Enumeration of human IL-10-producing B cells 
Mouse B10 cell frequencies have been described, with background cytoplasmic IL-10 staining of 
≤0.2% commonly observed with B cells from IL-10-/- mice.12,13,21 A similar strategy was 
therefore optimized to enumerate human blood IL-10-competent B cells. B cells spontaneously 
expressing IL-10 were below the threshold for reliable quantification by immunofluorescence 
staining, even when the cells were cultured with Brefeldin A to stop Golgi transport (Fig. 1A). 
However, a distinct subset of cytoplasmic IL-10+ B cell was observed at low 0.25-2% frequencies 
after ex vivo stimulation using phorbol ester and ionomycin plus Brefeldin A (PIB) (Fig. 1A-B). 
Stimulation with PIB for 5 h induced 0.8±0.1% of blood B cells on average to express IL-10 
(n=14, 1.9±0.3 x10-3 B10 cells/ml, Fig. 1B-C). B cell stimulation with TLR agonists did not 
substantially alter mean B10 cell numbers, although adding either CpG oligonucleotides (CpG, 
TLR9 agonist) or LPS to the PIB cultures increased IL-10+ B cell frequencies in some individuals 
(Fig. 1A-C). Stimulation beyond 5 h or using 10-fold higher PMA or ionomycin concentrations 
resulted in extensive B cell death, which complicated B10 cell enumeration. Background IL-10 
mAb staining was also reduced by the exclusion of cell doublets and dead cells from the analysis. 
Brefeldin A was also used to block IL-10 secretion rather than monensin since it optimized 
human B cell cytoplasmic IL-10 expression (Fig. 1A). B cells cultured in brefeldin A served as 
negative controls since they gave results similar to isotype control mAb staining. Thus, blood 
B10 cells were rare but readily quantified in healthy humans. 
 
Human B10pro cell identification 
In mice, B10pro cell maturation into IL-10-competent B10 cells is induced by 48 h stimulation 
with either LPS or agonistic CD40 mAb.21 Human blood B10pro cells capable of maturing into 
IL-10 competent cells after in vitro culture were also identified. The total frequency of B10 and 
B10pro cells (B10+B10pro) is quantified in this assay, as the B cells that acquire IL-10 
competence in vitro (e.g. matured B10pro cells) cannot be differentiated from preexisting B10 
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cells that inherently express cytoplasmic IL-10 after 5 h PIB stimulation. Culturing human B 
cells in media alone for 48 h resulted in ~0.2% of B cells expressing cytoplasmic IL-10 following 
PIB stimulation during the last 5 h of culture (Fig. 1B). Adding LPS, CpG, or recombinant CD40 
ligand (CD40L, CD154) alone, together, or in combination with brefeldin A to the 48 h cultures 
did not increase IL-10-producing B10 cell frequencies. However, following PIB stimulation 
during the last 5 h of culture, B10+B10pro cell frequencies increased to 0.6±0.1, 1.9±0.4, 0.8±0.1, 
1.2±0.2, and 4.1±1.0% following 48 h of TLR1 agonist, LPS, TLR6 agonist, TLR7 agonist, or 
CpG stimulation, respectively (Fig. 1E, left panel). When compared with media or most TLR 
agonists alone, the addition of CD40L to the cultures significantly enhanced mean B10+B10pro 
cell frequencies (Fig. 1E, right panel). CD40L induced higher IL-10+ B cell frequencies than 
agonistic CD40 mAb (Fig. 1D). Thus, dual CD40 and TLR stimulation induced the highest 
frequencies of B10pro cells to become IL-10 competent B10 cells, with the highest frequencies 
(7.0±1.4%) and numbers of IL-10+ cells (1.6±0.3 x 104 cells/ml, n=14) induced after 48 h of 
CD40L plus CpG stimulation. B10 cell percentages relative to all B cells decreased with age 
among 60 healthy individuals, with a significant inverse correlation between B10+B10pro cell 
frequencies and age (p<0.05, data not shown). Thus, B10pro cell maturation in vitro was required 
to optimally enumerate IL-10-competent B cell frequencies. 
 
B10 cell numbers in newborn blood and adult tissues 
Newborn blood contained both B10 and B10pro cells. Mean B10 cell frequencies in cord blood 
after 5 h of CpG+PIB stimulation were 0.45±0.14% (Fig. 2A). B10+B10pro cell frequencies 
were similar or higher in cord blood relative to adult blood after culture with CD40L and TLR 
agonists; TLR1 (2.6±0.6%), LPS (7.6±1.8%), TLR6 (4.2±1.4%), or TLR9 (CpG, 9.6±2.3%) 
agonists with PIB added during the final 5 h of culture. B10 cells were also found within spleens 
(0.31±0.06%, n=4, CpG+PIB) and tonsils (0.31±0.11%, n=3, CpG+PIB) of adults without known 
disease (Fig. 2B). Thus, newborn and adult blood and tissues contain quantifiable numbers of 
B10 and B10pro cells. 
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Regulation of B10 cell IL-10 production and secretion in vitro 
The time course of blood B cell IL-10 induction was assessed in vitro by quantifying IL-10 
transcripts. By 12, 24, and 48 h, B cell stimulation with CD40L plus CpG induced 6.8-, 24-, and 
5.9-fold higher Il10 transcript levels, respectively, than was observed for unstimulated B cells 
(p<0.05; Fig. 3A). Blood B cells that were actively secreting IL-10 after in vitro stimulation 
expressed Il10 transcripts at 19-fold higher levels than were detected in IL-10- B cells (Fig. 3B). 
Thus, Il10 gene transcription parallels the induction of B10 cell cytoplasmic IL-10 expression. 
The response of human B10+B10pro cells to CD40L, CpG, and antigen receptor generated 
signals was also examined. In comparison with CD40L alone, CpG induced the highest levels of 
B10pro cell maturation into IL-10-competent B10 cells, which was further increased when both 
CD40L and CpG were added to the cultures (Fig. 3C). By contrast, IgM ligation using mitogenic 
antibody did not induce cytoplasmic IL-10 expression, but actually inhibited the B10pro cell 
maturation effects of CpG+CD40L stimulation. In vitro IgM signals also inhibit mouse B10pro 
cell maturation and cytoplasmic IL-10 induction.21 Among TLR agonists, LPS and CpG were 
also the most potent stimuli for inducing IL-10 secretion by human blood B cells (Fig. 3D). The 
addition of CD40L to the cultures was not required, but enhanced LPS- and CpG-induced IL-10 
secretion. Thus, similar signals induce human and mouse B10pro and B10 cells to mature and 
express cytoplasmic IL-10 in vitro. 
 
Phenotypic characterization of IL-10-competent B cells 
Whether human B10 cells represent a unique or known B cell subset was determined by 
analyzing their cell surface phenotype. Cell surface IgM, IgD, CD1d, CD5, CD10, CD19, CD21, 
CD22, CD23, CD24, CD25, CD27, CD38, and CD40 densities did not change when B cells were 
stimulated with PIB, LPS+PIB, or CpG+PIB for 5 h, and/or permeabilized. Furthermore, the 
transport of newly synthesized proteins to the cell surface is inhibited by the addition of brefeldin 
A to the cultures. Therefore, these markers were used to phenotype freshly isolated B10 cells. 
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Half of blood B10 cells expressed high IgM levels and low IgD levels (Fig. 4A). Both CD24 and 
CD27 expression were high on the majority of B10 cells, while IL-10- B cells expressed either 
high or low density CD24 and CD27. CD19 and CD25 expression were also higher on B10 cells 
than IL-10- B cells. Otherwise, the remaining cell surface markers were absent or expressed 
similarly by both B10 cells and IL-10- B cells. The same results were obtained following PIB, 
LPS+PIB, or CpG+PIB stimulation (data not shown). Thereby, freshly isolated blood IL-10+ B10 
cells were predominantly found within the CD24hi or CD27+ B cell subpopulations. 
The phenotype of blood B10+B10pro cells was also assessed following 48 h of culture with 
CD40L+CpG, and 5 h of LPS+PIB stimulation. Prolonged B cell stimulation induced significant 
changes in the cell surface phenotype of both IL-10+ and IL-10- B cells, with most B cells 
induced to express CD25 and CD38 (Fig. 4B). Nonetheless, B10+B10pro cells on average 
expressed higher densities of CD1d, CD19, CD20, CD21, CD23, CD24, CD25, CD27, and 
CD38 when compared with IL-10- B cells, consistent with an activated phenotype. Spleen B10 
cells were also predominantly CD27+, although the expression of most cell surface molecules 
was similar if not identical for B10 cells and IL-10- B cells (Fig. 4C). Spleen B10+B10pro cells 
and IL-10- B cells also had similar phenotypes after 48 h of stimulation in vitro (Fig. 4D). 
Thereby, blood B10 cells represented a subset of the CD24hiCD27+ subpopulation, while IL-10 
expression remained the best marker for categorizing B10 cells and B10+B10pro cells. 
 
Blood B10 cells are enriched within the CD24hiCD27+ B cell subpopulation 
In addition to being predominantly CD24hi and CD27+, most B10 cells also expressed additional 
cell surface markers of activation (CD48hi) and memory (CD148hi) that were not affected by the 
5 h culture conditions used to induce B cell cytoplasmic IL-10 expression (Fig. 5A-B). Even 
when the spectrum of blood donors was compared, B10 cells were always predominantly CD24hi 
and CD27+ (Fig. 5C). Cell surface IgD, CD27, and CD38 expression profiles have also been used 
frequently to define human B cell subsets.37,38 However, when blood B10 cells were analyzed 
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based on their CD38 versus IgD, or CD27 versus IgD expression profiles, IL-10+ B10 cells from 
representative blood donors did not fall into distinct subpopulations (Fig. 5C).  
Since the CD24hiCD27+ B cell subpopulation represented 24±5% (n=7) of blood B cells on 
average, it was assessed whether CD24 and CD27 could be used as overlapping markers to 
enrich for B10 cells. When purified CD24hiCD27+ and CD24lowCD27- B cells were cultured 
individually with LPS+PIB for 5 h to induce IL-10 expression, B10 cell frequencies were >10-
fold higher within the CD24hiCD27+ subpopulation when compared with CD24lowCD27- B cells 
(Fig. 5D). To determine whether ex vivo B10pro cells also localize within the CD24hiCD27+ 
subpopulation, purified CD24hiCD27+ and CD24lowCD27- B cells were cultured individually to 
induce B10pro cell maturation. Again, the frequency of IL-10+ B10+B10pro cells was >10-fold 
higher within the CD24hiCD27+ subpopulation when compared with CD24lowCD27- cells (Fig. 
5E). The capacity of freshly isolated CD24hiCD27+ and CD24lowCD27- B cells to secrete IL-10 
was also assessed. Again, IL-10 was predominantly produced by the CD24hiCD27+ B cell 
subpopulation in response to CD40L, LPS, LPS+CD40L, CpG, or CpG+CD40L stimulation for 
72 h (Fig. 5F). Thus, blood B10 and B10pro cells predominantly represented a small subset of 
cells within the CD24hiCD27+ B cell subpopulation. 
Since B10 and B10pro cells express markers for activated and memory B cells, their ability to 
proliferate in response to mitogens was assessed. Purified blood B cells were labeled with CFSE 
before in vitro culture. There was little if any IL-10+ or IL-10- B cell proliferation during 48 h 
cultures regardless of whether the cells were stimulated with LPS or CpG. However, IL-10+ B 
cells exhibited a significant proliferative capacity in response to CpG at 96 h, while IL-10- B cell 
proliferation was modest (Fig. 5G). Thus, blood B10 and B10+B10pro cells preferentially 
proliferated in response to mitogen stimulation, consistent with their CD24hiCD27+ phenotype. 
 
B10 cells regulate innate immunity 
Resting or activated mouse B10 cells do not significantly influence mitogen-driven T cell 
activation or proliferation in vitro.22 However, activated B10 cells do inhibit TNF-α production 
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by antigen-specific CD4+ T cells during antigen-driven in vitro assays. In vitro T cell-B cell co-
culture systems were therefore assessed to determine whether human B10 cells regulate mitogen-
driven T cell function. First, purified blood CD24hiCD27+ B cells or CD24lowCD27- B cells were 
stimulated with CD40L and CpG for 24 h, washed extensively, and added to cultures of purified 
CD4+ T cells that were stimulated with plate-bound CD3 mAb for 72 h. In these assays, both 
CD24hiCD27+ B cells and CD24lowCD27- B cells inhibited CD4+ T cell expression of TNF-α 
equally (Fig. 6A). Unstimulated B cells did not affect CD4+ T cell expression of TNF-α  in these 
assays, and the addition of anti-IL-10 mAb to cultures containing activated CD24hiCD27+ or 
CD24lowCD27- B cells did not rescue TNF-α expression by CD4+ T cells (data not shown). Thus, 
activated human B cells can inhibit mitogen-induced TNF-α production by CD4+ T cells through 
IL-10-independent pathways that are not unique to CD24hiCD27+ B10 cells. 
Even though mouse B10 cell regulation of T cell function requires antigen-specific in vitro 
assays that are not amenable to human studies, we have found that mouse monocyte cytokine 
production is directly regulated by B10 cells through IL-10-dependent pathways that are not 
antigen-specific (M. Horikawa, et al., manuscript in preparation). The ability of human B10 cells 
to regulate innate monocyte responses was therefore assessed. Remarkably, TNF-α production 
was significantly reduced when monocytes were cultured with activated blood CD24hiCD27+ B 
cells and this effect was blocked by anti-IL-10 mAb (Fig. 6B). The addition of anti-IL-10 mAb to 
monocytes cultured alone did not affect TNF-α production (data not shown), while 
CD24lowCD27- B cells variably affected monocyte TNF-α production through IL-10-independent 
pathways. Thus, B10 cell production of IL-10 regulate monocyte cytokine production. 
 
B10 cells in patients with autoimmune disease 
To determine whether blood B10 cell numbers are altered during inflammation and autoimmune 
disease, B10 and B10pro cells were examined in 91 patients with systemic lupus erythematosis, 
rheumatoid arthritis, primary Sjögren’s syndrome, autoimmune vesiculobullous skin disease, or 
multiple sclerosis (Fig. 7A-B). Most patients were undergoing active treatment with 
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immunomodulatory agents and/or low doses of prednisone (Table 1). B10 cell frequencies were 
significantly higher in one pemphigus vulgaris patient (PV07) and one dermatitis herpetiformis 
patient (DH02) not undergoing immunosuppressive therapy. Two lupus patients (SLE02, SLE06) 
and one rheumatoid arthritis patient (RA03) also had significantly higher B10 cell frequencies, 
but retrospective evaluation of their disease status, autoantibody profile, and treatment regimen 
did not indicate why these individuals had higher B10 cell frequencies. No patients expressed 
significantly lower B10 cell frequencies than age-matched controls. Mean B10 cell frequencies 
were significantly higher for rheumatoid arthritis patients after culture with CpG but not for other 
patient groups (Fig 7B) even though B10 cell frequencies increased similarly in most cases after 
either LPS or CPG CpG stimulation (Fig. 7C, left panel). 
Mean B10+B10pro cell frequencies from patients with autoimmune disease were 
significantly higher than controls following either CD40L+LPS or CD40L+CpG stimulation (Fig. 
7A-B). Multiple patients had significantly higher B10+B10pro cell frequencies, including two 
patients not undergoing therapy (SLE04, PF03; Table 1). No patients expressed significantly 
lower B10+B10pro cell frequencies relative to age-matched controls. B10+B10pro cell 
frequencies increased following either LPS or CPG stimulation, but the scatter of the results was 
broad, suggesting inherently different patient sensitivities to LPS and CpG stimulation (Fig. 7C, 
right panel). Patients with high blood B10 cell frequencies did not necessarily have high 
B10+B10pro cell frequencies after either LPS or CpG stimulation (data not shown). Likewise, 
B10 or B10+B10pro cell frequencies did not correlate with CD27+ B cell frequencies (data not 
shown). Relative B10 and B10+B10pro cell frequencies did correlate with the intensity of 
cytoplasmic IL-10 expression, but only one patient generated significantly higher (p<0.05) 
cytoplasmic IL-10 expression levels on a per cell basis relative to controls and other patients (Fig. 
7D). Thus, blood B10 and B10pro cell numbers were not decreased in patients with systemic or 
organ-specific autoimmune disease when compared with healthy controls, but were significantly 
increased in some patients. 
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Discussion 
These studies demonstrate the existence of human IL-10-competent B10 cells, which were 
readily identified by their ability to express cytoplasmic IL-10 after in vitro stimulation for 5 h 
(Fig 1). Moreover, human B10 cells were able to regulate cytokine production by monocytes in 
vitro, demonstrating a functional link between regulatory B cells and the innate immune system 
(Fig. 6B). Peripheral blood B10 cell frequencies were characteristically low in most individuals, 
consistent with their low frequencies in mice. Human B10pro cells were also identified at low 
frequencies by their ability to express IL-10 after in vitro maturation during 48 h cultures. 
Remarkably, the adaptive and innate activation pathways that induced human B10 and B10pro 
cell generation, maturation, cytoplasmic IL-10 expression, and IL-10 secretion were similar to 
those used to characterize mouse regulatory B10 cells. Specifically, human B10 cells responded 
to phorbol ester/ionomycin, LPS and CpG stimulation, with B10pro cell maturation in response 
to CD40, LPS, and CpG induced signals. Previous studies of IL-10 production by human B cells 
have predominantly studied bulk B cell populations using stimulation and assay conditions that 
were not optimized for quantifying or characterizing individual B cells that were competent to 
express IL-10.25,26,39-43 Nonetheless, the results herein demonstrate that rare B10 and B10pro 
cells that are competent to express IL-10 exist in human blood and can be quantified in vitro. 
IL-10-competence remains the best phenotypic marker for defining human B10 cells. 
However, freshly isolated blood B10 and B10pro cells were also predominantly CD24hiCD27+, 
with ~60% also expressing CD38 (Fig. 5A, C). Others have found similar total numbers of IL-
10+ B cells in the CD24hiCD38hi and CD24intCD38int B cell fractions28, in agreement with the 
current findings (Fig. 5C). B10 cells also expressed CD48 and CD148 at high levels (Fig. 5A). 
CD48 is upregulated on activated B cells44 and CD148 is considered a marker for human 
memory B cells.45 CD27 expression is also a well-characterized marker for memory B cells, 
although some memory B cells may be CD27-.38,46,47 The CD27+ B cell subpopulation can also 
expand during the course of autoimmunity and may serve as a marker for disease activity.38,47 
However, B10 cell frequencies did not parallel the size of the blood CD27+ memory B cell pool 
 17 
in normal donors or patients (data not shown). Thus, the CD24hiCD27+ phenotype of B10 and 
B10pro cells may indicate their selection into the memory B cell pool during development or 
they may represent a distinct B cell subset that shares common cell surface markers with memory 
B cells. Consistent with a memory phenotype, the proliferative capacity of blood B10 cells in 
response to mitogen stimulation was higher than that for other B cells (Fig. 5F), as is seen for 
mouse B10 cells.21 Moreover, IL-10 was also predominantly secreted by ex vivo CD24hiCD27+ B 
cells (Fig. 5G). However, most CD24loCD27- B cells were not IL-10 competent, even after 48 h 
of LPS or CpG stimulation along with CD40 ligation. Human transitional B cells are also rare (2-
3% of B cells) in adult blood, and are generally CD10+CD24hiCD38hi cells that are also 
IgD+CD27-.48,49 Given that CD10 expression is a well-accepted marker for most cells within the 
transitional B cell pool.50, its absence on B10 cells suggests that these cells are not recent 
emigrants from the bone marrow. Thereby, in addition to inherent IL-10 competence, B10 cells 
demonstrate elevated proliferative responses that may reflect prior antigen stimulation.  
Since IL-10 is critical for B cell regulatory activity in mice, the current studies demonstrate 
that B10 cells were functionally competent to express IL-10 in healthy individuals and 91 
autoimmune disease patients (Fig. 7A-B). Blood B10 cell frequencies in most patients with lupus, 
rheumatoid arthritis, Sjögren’s syndrome, autoimmune skin disease, and multiple sclerosis were 
not significantly different from those observed in healthy controls, although mean B10+B10pro 
cell frequencies were significantly increased. Multiple patients also had significantly higher B10 
and/or B10+B10pro cell frequencies, including systemic lupus and pemphigus patients with 
either untreated or severe disease (Table 1). Consistent with this, IL-10 production by blood B 
cells is reported to be higher in patients with rheumatoid arthritis, lupus, and systemic 
sclerosis.23,24,26 Moreover, elevated B10/B10pro cell frequencies in humans parallels what has 
been found during inflammation12,13 and autoimmunity in mice.14,21 Although patient cohorts 
with recent-onset disease and clinically active disease across multiple organ systems will be 
needed to fully assess the relationship of blood B10 cell numbers with clinical, laboratory, and 
treatment status, none of the patients or patient groups had significantly lower blood B10 cell 
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numbers than age-matched healthy controls. Since multiple sclerosis and lupus patient’s B cells 
are reported to produce decreased amounts of IL-10,27,28 the current studies demonstrate that a 
careful enumeration of IL-10 competent B10 cell frequencies within patients will be required in 
order to interpret experimental results, particularly when mixed populations of B cells are 
assayed functionally. Blair et al. have also functionally characterized human blood CD24hiCD38hi 
B cells stimulated in vitro with CD40L expressing CHO cells and shown that they reduce CD4+ 
T cell expression of IFN-γ and TNF-α following T cell stimulation with CD3 mAb.28 By contrast, 
we find that both activated B10 and non-B10 cells reduce TNF-α expression following CD4+ T 
cell stimulation with CD3 mAb through IL-10-independent pathways (Fig. 6A). Nonetheless, we 
have found that mouse spleen CD1dhiCD5+ B cells can inhibit CD4+ T cell IFN-γ and TNF-α 
expression, which is completely dependent on IL-10 expression, but this requires B10 cell 
activation and is only observed with antigen-specific T cell activation.22 Furthermore, mouse 
spleen CD1dhiCD5+ B cells regulate the antigen-presenting capacity of dendritic cells in vitro, 
and can thereby also regulate CD4+ T cell activation indirectly.22 Moreover, the ability of human 
B10 cells to influence innate monocyte function (Fig. 6B) expands their regulatory role during 
immunity and disease. Thus, it is likely that IL-10 produced by human B10 cells will have 
pleiotropic regulatory effects on the immune system as occurs in mice. 
In summary, the current findings demonstrate the existence of a small but significant subset 
of CD24hiCD27+ B cells that is pre-programmed in vivo to express IL-10 after ex vivo 
maturation/stimulation. Monitoring the numbers and ability of individual B10 cells to produce 
IL-10 will become even more informative once the in vivo physiologic triggers of B10 cell 
regulatory activity are identified. The identification of antigen-specific B10 cells may also 
facilitate a further understanding of their relevance to immune responsiveness since antigen 
receptor specificity is important for mouse B10 cell development and in vivo functional activity 
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Table 1. Patient characteristics. 
Diagnosis
Number 
Sex Age Disease 
Duration (y) 
Autoantibody/Clinical Status Immunosuppressive 
Therapy 
RA011 M 54 11 RF=600 IU/ml; anti-CCP=68.5 U/ml MTX, ADA, Pred 5 mg/d 
RA02 F 44 4 RF=352 IU/ml; anti-CCP>100 U/ml MTX 
RA03 F 54 14 RF=146 IU/mL MTX, LEF 
RA04 F 85 18 RF=neg MTX, IFX 
RA05 M 69 19 RF=208 IU/ml; anti-CCP>100 U/ml MTX, Pred 5 mg/d 
RA06 F 71 8 RF=neg MTX 
RA07 F 67 13 RF=333 IU/ml ETN 
RA08 F 58 25 RF=53 IU/ml MTX, ETN, Pred 3 mg/d 
RA09 F 68 7 RF=339 IU/ml MTX, Pred 3 mg/d 
RA10 M 75 13 RF=420 IU/ml; anti-CCP=18.9 U/ml MTX, LEF, Pred 10 mg/d 
RA11 F 73 7 RF and anti-CCP=neg MTX, LEF 
RA12 M 61 27 RF=107 IU/ml MTX, LEF 
RA13 F 66 6 RF=pos ADA 
RA14 F 84 11 RF=275 IU/ml; anti-CCP=28 U/ml ETN 
RA15 F 52 3 RF=neg; anti-CCP>100 U/ml ETN 
RA16 F 76 18 RF=pos MTX 
RA17 M 63 11 RF=neg; anti-CCP>100 U/ml MTX, SSZ, Pred 1 mg/d 
RA18 F 43 15 RF=23 IU/ml MTX, IFX 
RA19 F 62 30 RF=148 IU/ml; anti-CCP>100 U/ml LEF; Pred 5 mg/d 
SLE01 F 65 11 ANA=1:2560; IgG CL and anti-dsDNA= pos HCQ, LEF, Pred 5 mg/d 
SLE02 M 31 3 ANA=1:640; anti-RNP, anti-Sm, and anti-Ro=pos HCQ, Pred 3 mg/d 
SLE03 M 63 32 ANA=1:640; anti-dsDNA and IgG anti-CL= pos HCQ, Pred 5 mg/d 
SLE04 F 37 5 ANA=1:2560; anti-Ro=pos None 
SLE05 F 43 15 ANA=1:160; RF=36 IU/ml HCQ, MMF 
SLE06 F 46 8 ANA=pos; anti-Ro=pos MMF 2 g/d, Pred 10 mg/d 
SLE07 M 31 23 ANA=1:160; anti-dsDNA and IgG anti-CL=pos HCQ 
SLE08 F 47 10 ANA=1:2560; anti-dsDNA, anti-Ro and anti-La=pos; 
RF=103 IU/ml 
None 
SLE09 F 37 16 ANA=pos; anti-dsDNA, anti-IgM and IgG CL=pos HCQ; Pred 10 mg/d 
SLE10 F 48 7 ANA=1:2560; anti-dsDNA, anti-Ro and anti-La =pos Pred 5 mg/d 
SLE11 F 37 25 ANA=1:640 HCQ 
SLE12 F 49 6 ANA=1:640; anti-dsDNA and anti-Ro=pos HCQ 
SLE13 F 48 20 ANA=1:640; anti-dsDNA and anti-Ro=pos Pred 5 mg/d 
SLE14 F 58 13 ANA=pos; anti-dsDNA, anti-Ro and anti-La=pos MMF, HCQ, Pred 10 mg/d 
SjS01 F 52 1 ANA=1:2560; RF=354 IU/ml; anti-Ro and anti-La=pos None 
SjS02 F 65 15 ANA=1:2560; RF=22 IU/ml; anti-Ro= pos HCQ 
SjS03 F 57 37 ANA=1:160; anti-Ro=pos MMF, Pred 40 mg/d 
SjS04 F 67 22 ANA=1:2560; RF 110 IU/ml, anti-Ro and anti-La=pos HCQ 
SjS05 F 60 9 ANA=1:2560; RF=126 IU/ml, anti-Ro=pos HCQ 
SjS06 F 58 21 ANA=1:2560; anti-Ro and anti-La=pos None 
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SjS07 F 41 13 ANA=1:2560; anti-Ro and anti-La=pos HCQ 
SjS08 F 59 8 ANA=1:2560; RF=508 IU/ml; anti-Ro=pos None 
SjS09 F 42 4 ANA=1:2560; RF=110 IU/ml; anti-Ro and anti-La=pos HCQ 
SjS10 F 58 5 ANA=1:2560; anti-Ro and anti-La=pos HCQ, Pred 3 mg/d 
SjS11 M 66 5 ANA=1:2560; anti-Ro and anti-La=pos None 
SjS12 F 76 13 ANA=1:2560; anti-Ro=pos; RF=32 IU/ml None 
SjS13 M 51 1 ANA=1:160 HCQ 
SjS14 F 68 28 ANA=1:2560; anti-Ro=pos HCQ 
SjS15 F 66 12 ANA=1:2560 None 
SjS16 F 64 8 ANA=1:2560; anti-Ro=pos None 
SjS17 F 78 13 ANA=pos; anti-Ro=pos HCQ 
BP01 M 72 0.3 Anti-BP180=84 U/ml; anti-BP230=115 U/ml, no clinical 
disease 
Pred 60 mg/d 
BP02 M 54 1.2 Anti-BP180=72 U/ml; anti-BP230=neg, no clinical disease MMF, Pred 12 mg/d 
BP03 F 56 2 Anti-BP180=51 U/ml; anti-BP230=neg, no clinical disease Pred 20 mg/d 
BP04 M 75 4.3 Anti-BP180=45 U/ml; anti-BP230=3, mild disease None 
BP05 F 66 1.8 Anti-BP180=96 U/ml; anti-BP230=131, severe disease None 
BP06 M 77 0.5 Anti-BP180=5 U/ml; anti-BP230=95, mild disease None 
BP07 F 67 17 Anti-BP180=46 U/ml; anti-BP230=neg, mild disease RTX (20 mos earlier) 
BP08 F 54 2 Anti-BP180=22 U/ml; anti-BP230=7, no clinical disease RTX (13 mos earlier), Pred 
15 mg/d 
BP09 F 62 5.4 Anti-BP180=30 U/ml; anti-BP230=3, mild disease RTX (52 mos earlier) 
BP10 M 73 0.25 Anti-BP180=222 U/ml; anti-BP230=7, no clinical disease Pred 50 mg/d 
PF01 M 54 8.6 Anti-DSG1=134 U/ml; anti-DSG3=neg, mild disease 
activity 
AZA 
PF02 M 55 9.8 Anti-DSG1=neg; anti-DSG3=neg, mild disease activity RTX (30 mos earlier) 
PF03 M 46 6.6 Anti-DSG1=416; anti-DSG3=neg, moderate disease 
activity  
None 
PF04 M 50 5.3 Anti-DSG1=1906; anti-DSG3=neg, moderate disease 
activity 
MMF  
PF05 M 72 2.8 Anti-DSG1=118; anti-DSG3=neg, no clinical disease Dapsone 100 mg/d 
PF06 F 47 0.4 Anti-DSG1=211; anti-DSG3=neg, moderate clinical 
disease activity 
Pred 40 mg/d 
PV02 M 43 3 Anti-DSG1=neg; anti-DSG3=213 U/ml, moderate oral 
disease activity  
MMF, Pred 20 mg/d 
PV03 M 73 3.3 Anti-DSG1=neg; anti-DSG3=948 U/ml, mild oral disease Pred 12 mg/d 
PV04 F 55 4.7 Anti-DSG1=neg; anti-DSG3=406 U/ml, moderate oral 
disease activity 
RTX (15 mos earlier) 
PV05 M 59 8.3 Anti-DSG1=neg; anti-DSG3=50 U/ml, no disease activity AZA 
PV06 F 48 8.6 Anti-DSG1=neg; anti-DSG3=25 U/ml, no disease activity None 
PV07 M 45 0.25 Anti-DSG1=968; anti-DSG3=735, severe disease 
involving 20% of the skin 
MMF; Pred 80 mg/d 
PV08 M 84 0.2 Anti-DSG1=75; anti-DSG3=146 U/ml, moderate disease None 
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activity  
PV09 M 64 9.8 Anti-DSG1=14; anti-DSG3=115 U/ml, mild disease 
activity 
Pred 20 mg/d; IFX 
PV10 M 59 3.8 Anti-DSG1=1; anti-DSG3=49 U/ml, no disease activity AZA 
PV11 M 55 6 Anti-DSG1=34; anti-DSG3=35 U/ml, mild oral disease 
activity 
Pred 20 mg/d; MMF  
PV12 F 58 9.5 Anti-DSG1=1; anti-DSG3=43 U/ml, mild oral disease 
activity 
AZA 
PV13 M 75 5 Anti-DSG1=1; anti-DSG3=42 U/ml, mild disease RTX (6 mos earlier), Pred 
1 mg/d 
PV14 M 70 8.4 Anti-DSG1=110; anti-DSG3=113 U/ml, no clinical disease AZA 
PV15 F 37 0.3 Anti-DSG1=104; anti-DSG3=810 U/ml, moderate disease 
activity 
Pred 40 mg/d 
PV16 M 78 15 Anti-DSG1=297; anti-DSG3=447 U/ml, moderate disease 
activity 
None 
DH1 F 65 8.4 Gluten-free diet, no clinical disease Dapsone 25 mg/d 
DH2 M 40 30 normal diet, no clinical disease Dapsone175 mg/d 
MS01 F 72 54 SPMS, EDSS 6.5, not clinically active None 
MS02 M 62 24 RRMS, EDSS 6.5, clinically active BIFN 
MS03 M 33 2 RRMS, EDSS 1.0, disease not clinically active BIFN 
MS04 M 75 29 SPMS, EDSS 8.0, disease not clinically active ITMTX 
MS05 M 52 24 PPMS, EDSS 6.5, disease clinically active MMF, pulse steroids 
MS06 M 55 25 PPMS, EDSS 7.5, disease clinically active ITMTX 
MS07 F 39 16 SPMS, EDSS 7.0, disease not clinically active Natalizumab (2 mos prior) 
MS08 F 51 7 SPMS, EDSS 5.5, disease not clinically active BIFN 
1Abbreviations: ANA, antinuclear Ab; ADA, adalimumab; AZA, azathioprine; BIFN, beta 
interferon; BP, bullous pemphigoid; CCP, cyclic citrullinated peptide; CL, cardiolipin; DH, 
dermatitis herpetiformis; dsDNA, double stranded DNA; DSG, desmoglein; EDSS, disability 
scale from 0=normal to 10=death; ETN, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; 
ITMTX, intrathecal methotrexate; LEF, leflunomide; MMF, mycophenolate mofetil; MTX, 
methotrexate; PF, pemphigus foliaceus; PPMS, primary progressive multiple sclerosis; Pred, 
Prednisone; PV, pemphigus vulgaris; RA, rheumatoid arthritis; RF, rheumatoid factor; RRMS, 
relapsing remitting multiple sclerosis; RTX, rituximab; SjS, primary Sjögren’s syndrome; SLE, 
lupus; SPMS, secondary progressive multiple sclerosis; SSZ, sulfasalazine; y, year. 
2Normal values: anti-BP=180, anti-BP=230, anti-DSG1 and anti-DSG3 antibodies <9 IU/ml. 
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Figure Legends 
Figure 1. Enumeration of human blood IL-10-competent B10 and B10pro cells. (A) Visualizing 
IL-10+ B cells. Purified blood mononuclear cells were cultured with Brefeldin A (BFA), LPS 
plus PMA, ionomycin and Brefeldin A (PIB), or LPS plus PMA, ionomycin and monensin (PIM) 
for 5 h and stained for cell viability, cell surface CD19 expression, and cytoplasmic IL-10. 
Representative cytoplasmic IL-10 staining by viable, single CD19+ B cells is shown in the flow 
cytometry dot-plots, with percentages indicating cytoplasmic IL-10+ B cell frequencies within the 
indicated gates. Blood mononuclear cells that were cultured with Brefeldin A alone before 
immunofluorescence staining served as negative controls, with background staining similar to 
that obtained using isotype-matched control mAbs. Bar graphs represent mean (±SEM) B10 cell 
frequencies from 3 individuals. (B) Representative IL-10 production by B cells from an 
individual with relatively high B10 cell frequencies. B10 cells were identified after in vitro 
stimulation for 5 h as in (A). Alternatively, IL-10+ B cell frequencies were determined after in 
vitro B10pro cell maturation by stimulation with LPS, CD40L+LPS, CpG, or CD40L+CpG, with 
PIB added during the final 5 h of 48 h cultures. As negative controls for IL-10 staining, only BFA 
was added to some cultures during the final 5 h. Percentages indicate the frequencies of 
cytoplasmic IL-10+ B cells within the indicated gates among total CD19+ B cells. (C) B10 cell 
frequencies in individuals after with TLR agonist stimulation as in (A-B). Dots represent results 
from single individuals after 5 h culture with BFA alone, PIB, or the indicated TLR agonist+PIB. 
Horizontal bars indicate means. (D) CD40L induced optimal B10+B10pro cell maturation during 
48 h in vitro cultures with either recombinant CD40L or CD40 mAb, plus LPS for 48 h, with PIB 
added during the final 5 h. Bar graphs represent means (±SEM) from 5 individuals. Similar 
results were obtained in 2 independent experiments. (E) Representative B10+B10pro cell 
frequencies after in vitro maturation and stimulation. Blood mononuclear cells were cultured for 
48 h with media alone or media containing CD40L, along with the indicated TLR agonists, with 
PIB added during the last 5 h of culture. Significant differences between cultures with or without 
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CD40L are indicated: #p<0.05, ##p<0.01. (C-E) Significant differences between means of 
controls and individual stimuli are indicated: *p<0.05, **p<0.01. 
 
Figure 2. Human B10 and B10pro cells in (A) cord blood, and (B) spleen and tonsil. B10 cells 
and B10+B10pro cells were identified after in vitro stimulation for 5 h and 48 h, respectively, as 
in figure 1. Representative results are shown along with graphs indicating IL-10+ B cell 
frequencies within individuals. Cells cultured with BFA alone served as negative controls for 
background IL-10 staining. Significant differences between means of BFA controls and 
individual stimuli are indicated: *p<0.05, **p<0.01. 
 
Figure 3. Blood B cell stimulation induces IL-10 transcription and secretion in vitro. (A) Time 
course of Il10 transcript induction. Purified CD19+ B cells were cultured with media alone or 
CD40L+CpG for the times indicated, with Il10 transcripts quantified by real-time RT-PCR 
analysis. Bar graphs indicate mean relative Il10 transcript (±SEM) levels in six individuals. (B) B 
cells secreting IL-10 express Il10 transcripts. Purified blood B cells were cultured with PMA and 
ionomycin for 4 h before CD19 staining and secreted IL-10 capture (left panel). Cell surface IL-
10+ and IL-10- B cells were isolated using the indicated gates and subsequently reassessed for IL-
10 secretion (right panels) before relative Il10 transcript levels were quantified by real-time RT-
PCR analysis. Mean fold-differences (±SEM) for Il10 transcript levels from 3 different 
individuals are shown, with transcript levels normalized so that the relative mean IL-10- B cell 
value is 1.0. (C) Cell surface signals that regulate cytoplasmic IL-10 expression. Blood B cells 
were cultured with CpG, CD40L, and anti-IgM Ab (IgM) as indicated for 48 h with PIB added 
during the final 5 h of culture. Representative frequencies of IL-10-producing cells are shown, 
with bar graphs indicating mean (±SEM) percentages in 5 individuals. (D) TLR agonists that 
induce IL-10 secretion. Purified CD19+ B cells were cultured with media alone, CD40L, or with 
TLR agonists and CD40L as indicated for 48 or 72 h. IL-10 secreted into the culture supernatant 
fluid was quantified by ELISA. Bar graphs indicate mean IL-10 (±SEM) concentrations from ≥4 
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different individuals. (A-D) Similar results were obtained in 2 independent experiments. 
Significant differences between means of cells cultured in media alone and stimulated cultures 
are indicated: *p<0.05, **, p<0.01. 
 
Figure 4. Phenotypes of blood and tissue B10 cells ex vivo and B10+B10pro cells after in vitro 
culture. (A) Representative cell surface phenotype of blood B cells cultured with LPS+PIB for 5 
h. (B) Representative cell surface phenotype of blood B10+B10pro cells after stimulation with 
CD40L+LPS for 48 h with PIB added during the final 5 h of culture. (C) Representative cell 
surface phenotype of spleen B10 cells cultured with CpG+PIB for 5 h. (D) Representative cell 
surface phenotype of spleen B10+B10pro cells after stimulation with CD40L+CpG for 48 h with 
PIB added during the final 5 h of culture. (A-D) Cultured cells were stained for viability and cell 
surface molecule expression, permeabilized, stained with anti-IL-10 mAb, and analyzed by flow 
cytometry. Representative cell surface molecule expression by IL-10+ (thick line) and IL10- (thin 
line) CD19+ B cells from three individuals is shown. Shaded histograms represent isotype-
matched control mAb staining. 
 
Figure 5. Ex vivo blood B10 and B10pro cells share cell surface markers with memory B cells. 
(A) Blood B10 cells predominantly exhibit a CD24hiCD27+CD48hiCD148hi phenotype. Purified 
blood B cells were cultured with CpG+PIB for 5 h before immunofluorescence staining for 
viability, cell surface molecule expression, and cytoplasmic IL-10. Cell surface CD24, CD27, 
CD38, CD48, and CD148 expression by IL-10+ (thick line) and IL-10- (thin line) CD19+ cells 
was assessed by flow cytometry. (B) Cytoplasmic IL-10 induction does not affect the cell surface 
phenotype of B cells. CD19+ blood B cells were cultured with media on ice (thin line) or with 
CpG+PIB (thick line) for 5 h before immunofluorescence staining and flow cytometry analysis as 
in (A). (A-B) Shaded histograms represent isotype-matched control mAb staining. Results 
represent those obtained for 3 individuals. (C) Distributions of B10 cells within B cell subsets 
defined by CD24, CD27, IgD/CD38, and IgD/CD27 expression. Purified blood B cells were 
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cultured with LPS+PIB for 5 h before immunofluorescence staining and flow cytometry analysis 
as in (A). The horizontal and vertical lines on each contour plot are shown for reference, with the 
lower left quadrants delineating the IgD-CD38- and IgD-CD27- subsets determined by control 
mAb staining. Results represent those obtained for 5 individuals. (D) The ex vivo CD24hiCD27+ 
B cell subset includes the majority of B10 cells. Purified B cells were cultured with LPS+PIB for 
5 h before immunofluorescence staining for cell surface CD19, CD24, and CD27 expression and 
cytoplasmic IL-10 expression, with subsequent flow cytometry analysis. (E) B10pro cells derive 
from the CD24hiCD27+ B cell subset. Purified blood B cells were sorted into the CD24hiCD27+ 
and CD24lowCD27- B cell subsets as indicated by the gates shown with purities >90% when 
reanalyzed by flow cytometry. The purified B cells were cultured with CD40L plus either LPS or 
CpG for 48 h, with PIB added during the final 5 h of culture before the relative percentages of IL-
10+ B cells within the indicated gates was determined. Similar results were obtained in 2 
independent experiments. (F) Ex vivo CD24hiCD27+ B cells are the predominant source of 
secreted IL-10. Purified blood B cells were sorted into the CD24hiCD27+ and CD24lowCD27- B 
cell subsets as in (E) and cultured with the indicated stimuli for 72 h. IL-10 secreted into the 
culture supernatant fluid was quantified by ELISA. Bar graphs indicate mean IL-10 (±SEM) 
concentrations from triplicate ELISA determinations. Significant differences between means 
from CD24hiCD27+ and CD24lowCD27- B cells are indicated: **, p<0.01. Differences between 
means from cells in media or with stimuli are indicated: ##, p<0.01. (G) B10 cell proliferation in 
vitro. Blood mononuclear cells were labeled with CFSE and cultured with CD40L and CPG (top 
panels) or CD40L and LPS (top panels) for 48-96 h, with PIB added for the last 5 h of culture. 
Histograms (right) represent CFSE expression by the IL-10+ (thick line) or IL-10- (thin line) B 
cell subsets. Results are representative of two independent experiments.  
 
Figure 6. B10 cell regulation of innate immunity. (A) B10 cell effects on mitogen-stimulated T 
cell cytokine production. Purified blood CD24hiCD27+ or CD24lowCD27- B cells were stimulated 
with CD40L plus CpG for 24 h, isolated, and then cultured with CD3 mAb-stimulated CD4+ T 
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cells for 72 h. After PMA plus ionomycin stimulation, CD4+ T cell TNF-α expression was 
assessed by flow cytometry (heavy lines). CD4+ T cells cultured alone are shown as positive 
controls (thin lines). Background cell staining using unstimulated T cells is shown (shaded lines) 
(B) B10 cells regulate monocyte cytokine production. Purified blood CD24hiCD27+ or 
CD24+CD27- B cells were stimulated with CD40L plus CpG for 24 h, and were cultured with 
blood monocytes for 20 h before cytoplasmic TNF-α expression by CD14+ monocytes was 
assessed after 4 h of LPS stimulation (heavy lines). Anti-IL-10 mAb was added to some cultures 
as indicated (dashed lines). Monocytes cultured alone are shown as positive controls (thin lines), 
with background cell staining using unstimulated monocytes shown (shaded lines). (A, B) 
Results represent those obtained in ≥2 independent experiments. 
 
Figure 7. Blood B10 cell frequencies in patients with autoimmune disease. (A) Representative B 
cell cytoplasmic IL-10 expression by control (Ctrl) individuals, and lupus (SLE), rheumatoid 
arthritis (RA), Sjögren’s syndrome (SjS), blistering skin disease (BD), and multiple sclerosis 
(MS) patients with relatively high B10 cell frequencies after in vitro CpG+PIB stimulation for 5 
h. B10+B10pro cell maturation was induced by 48 h CD40L+CpG stimulation, with PIB added 
during the final 5 h of culture. Percentages indicate IL-10+ B cell frequencies among CD19+ B 
cells. (B) IL-10+ B cell frequencies as in (A) with each dot representing single individuals. 
Horizontal bars indicate group means. The solid horizontal lines indicate means plus 2 SD (95% 
confidence interval) for controls, while dashed lines represent means plus 2 SD for all values. 
The patients are described in Table 1. Significant differences between means of patient groups 
and healthy controls are indicated: *p<0.05, **, p<0.01. (C) Relative frequencies of B10 cells 
and B10+B10pro cells identified for control individuals and patients with autoimmune disease as 
in (B) compared after CpG or LPS stimulation with each dot representing an individual. (D) 
Relationship between cytoplasmic IL-10 expression levels and B10+B10pro cell frequencies in 
control individuals and patients after stimulation with CD40L+CpG, with PIB added during the 
final 5 h of 48 h cultures. Linear mean fluorescence intensities (MFI) for IL-10+ and IL-10- B 
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cells were determined using the gates indicated in (A) with the values shown representing a ratio 
of IL-10+ to IL-10- MFIs. A linear regression line (± 95% prediction bands, dashed lines) is 
shown for reference. 
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